Based on the aforementioned experimental data, Gayathri et al. 78 constructed recombinant viruses expressing checkpoint inhibitor antibodies (rNDV-anti-PD1 and rNDV-anti-PDL1) with NDV as the vector for the first time and tested the therapeutic effect on a mouse melanoma model by administering the virus with different combinations of systemic CTLA4 blockers. The gene discussed is CTLA4; the disease is melanoma.